Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep 30;19(3):77-88.
doi: 10.31083/j.rcm.2018.03.908.

Alteration of lipid metabolism in chronic kidney disease, the role of novel antihyperlipidemic agents, and future directions

Sivakumar Sudhakaran  1   2   3   4 , Teodoro Bottiglieri  2   3   4   5 , Kristen M Tecson  2   3   4   5 , Aaron Y Kluger  2   3   4   5 , Peter A McCullough  1   2   3   4   5
Affiliations
Free article
Review

Alteration of lipid metabolism in chronic kidney disease, the role of novel antihyperlipidemic agents, and future directions

Sivakumar Sudhakaran et al. Rev Cardiovasc Med. .
Free article

Abstract

The role of anti-hyperlipidemic therapy remains of key importance in the treatment of atherosclerotic disease. Moreover, given an already exaggerated predisposition for vascular disease at baseline, there is a preponderance of data that show management of hyperlipidemia is especially important in patients with chronic kidney disease. This is a concise, up-to-date review of lipid physiology, alterations in lipid concentrations with progressive renal failure, and currently available and emerging hyperlipidemic treatment options. Specifically, the roles of these therapies in patients with chronic kidney disease are reviewed.

Keywords: Hyperlipidemia; PCSK9; chronic kidney disease (CKD); hyperlipidemia in CKD; hyperlipidemia management; lipid physiology.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

MeSH terms

LinkOut - more resources